MOTS-c vs SS-31: what the mitochondrial peptide hype misses

What's this video probably claiming?

Dr. Nick is almost certainly framing MOTS-c and SS-31 as the next tier of mitochondrial optimization peptides, likely positioning one as superior depending on your goal. The pitch probably goes something like this: MOTS-c for metabolic and exercise performance benefits, SS-31 (also known as elamipretide) for deeper mitochondrial membrane repair and age-related decline. These are genuinely interesting molecules, and a physician-creator in the peptide therapy space has good reason to talk about them. But the framing of "which is better" is already a problem, because these peptides work through different mechanisms, have been studied in wildly different contexts, and neither has cleared clinical trials in healthy adults for anti-aging purposes. The comparison framing suggests interchangeability or a head-to-head clinical rivalry that simply does not exist in the published literature.

What does the science actually show?

MOTS-c is a mitochondrial-derived peptide encoded in the 12S rRNA region of mitochondrial DNA. Lee et al. (2015, Cell Metabolism) showed it regulates glucose and fatty acid metabolism in mice, reducing obesity and improving insulin sensitivity. A follow-up by Reynolds et al. (2021, Nature Communications) found MOTS-c levels decline with age in humans and that exogenous administration improved physical performance in older male mice. That is legitimately interesting. SS-31, meanwhile, targets cardiolipin on the inner mitochondrial membrane. Szeto et al. (2014, Journal of Cardiovascular Pharmacology) demonstrated it reduces oxidative stress and mitochondrial dysfunction in cardiac models. A small human trial by Bhatt et al. (2017, JCI Insight) tested SS-31 in heart failure patients, showing improved mitochondrial energetics. Both peptides have real mechanistic data. Neither has a completed Phase 3 trial in humans for longevity or general anti-aging indications.

Where does the social media noise diverge from clinical reality?

Here is where the "which is better" framing breaks down completely. MOTS-c human data is almost entirely observational or derived from rodent models. The Reynolds 2021 paper generated significant buzz, but the human component measured circulating MOTS-c levels as a biomarker, not the effect of injecting exogenous MOTS-c into people. SS-31 has gone further in clinical development but specifically for heart failure, Barth syndrome, and mitochondrial myopathy, not for healthy adults who want to feel 10 years younger. Steele et al. (2020, NEJM Evidence) ran elamipretide trials in Barth syndrome patients with mixed results. The leap from "this helped a child with a rare mitochondrial disease" to "this will optimize your training" is not supported by data. Compounded versions of these peptides circulating in the wellness market also have no validated dosing protocols in healthy human populations. That is not a minor caveat.

What should you actually know?

Both MOTS-c and SS-31 represent genuinely novel biology. Mitochondrial-derived peptides are a real and emerging area of research, and the mechanistic logic is sound. But mechanism is not efficacy, and efficacy in rodents or rare disease patients is not efficacy in a healthy 45-year-old. No regulatory body has approved either peptide for anti-aging or general wellness use. Compounded versions exist in gray-market peptide supply chains with no standardized purity or dosing verification. Anyone receiving these outside of a supervised clinical trial is essentially self-experimenting with molecules that lack human safety data at the doses being used in practice. If you are genuinely interested in mitochondrial health, the lifestyle interventions with the most human evidence, including exercise training, caloric restriction, and sleep optimization, remain considerably better supported than any injectable peptide currently on the market.